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We analysed the first 84 coronavirus disease (COVID-
19) patients hospitalised in an infectious and tropical 
disease unit in Florence, Italy, over 30 days after the 
start of the COVID-19 outbreak in Italy. A 12% reduction 
in the rate of intensive care unit transfer was observed 
after the implementation of intensity care measures in 
the regular ward such as increasing the nurse/patient 
ratio, presence of critical care physicians and using 
high flow nasal cannulae oxygenation.
Since the first case reported on 21 February 2020 in 
Lombardia region, Italy has become one of the coun-
tries most affected by the coronavirus disease (COVID-
19) pandemic, counting more than 197,000 cases and 
more than 26,000 fatalities by 27 April. At the end 
of April, Italy has the highest numbers of confirmed 
deaths in Europe [1,2].
We present our first-month experience of the COVID-19 
pandemic in Italy at the Infectious and Tropical Disease 
Unit (ITD) of the University Hospital in Florence, 
Tuscany. We aimed to describe clinical and demo-
graphic characteristics of hospitalised patients with 
COVID-19 as well as differences between hospitalised 
patients not transferred to the intensive care unit (ICU) 
and hospitalised patients later transferred to the ICU. 
Finally, we analysed the incidence rate of ICU trans-
fers before and after the implementation of additional 
intensity care measures on our regular ward.
 
Construction of the cohort and data 
analysis
We enrolled all laboratory-confirmed COVID-19 cases 
who were hospitalised in the ITD ward between 25 
February and 26 March 2020. A laboratory-confirmed 
case was a symptomatic patient with positive result on 
a reverse-transcriptase (RT)-PCR assay. Demographic 
and clinical data were collected from electronic medi-
cal hospital records. ICU transfer was the primary 
outcome. Categorical variables were analysed by chi-
squared or Fisher’s exact test and continuous variables 
by the Kruskal-Wallis test. Poisson regression model 
was used for regression analysis. Cases were followed-
up from the first day of hospitalisation to ICU transfer 
or hospital discharge or death. Cases still hospitalised 
were censored on 3 April.
Data collection was approved by the local Ethics 
Committee (17104_oss). The study was performed in 
accordance with the ethical principles of the Declaration 
of Helsinki and with the International Conference on 
Harmonization Good Clinical Practice guidelines.
Rising intensity of care: pre- and 
post-intervention
Since the beginning of the COVID-19 outbreak in Italy, the 
intensity care level in the ITD was gradually increased. 
Under standard operations, hereafter referred to as 
‘pre-intervention’, our ward has a nurse-patient ratio 
of 1:10. Thirteen days after hospitalisation of the first 
COVID-19 case, hereafter referred to as ‘post-interven-
tion’, the nurse patient ratio was enhanced to 1:6, a 
stable team of critical care physicians was formed, and 
2 www.eurosurveillance.org
advanced ventilation support like high flow nasal can-
nulae oxygenation became available on the ward.
Cohort description
Overall, we included 84 patients: 16 (19.0%) were 
admitted in ICU, while 68 (81.0%) did not (N-ICU). All 
ICU patients underwent invasive mechanical ventila-
tion. At the data cut-off date, eight had died (9.5%), 
57* were discharged (67.9%), and 19 (22.6%) were 
still hospitalised (six in our unit and 13 in ICU). The 
median age of cases was 62 years (interquartile range 
(IQR): 51–72), 55 (65.5%) of cases were males and 49 
(58.3%) had at least one comorbidity. The comorbidi-
ties or conditions mainly associated with ICU transfer 
were having chronic obstructive pulmonary disease 
(COPD) (p = 0.016) and presenting with low Horowitz 
index (PaO2/FiO2 ratio) at admission (p = 0.0048). All 
ICU cases had radiologically confirmed pneumonia. 
Table 1
Clinical and demographic characteristics at admission of hospitalised COVID-19 cases at the infectious and tropical 














n % or (IQR) n % or (IQR) n % or (IQR)
Age and sex
Age, median (years) 62 (51–72) 62 (50–72) 67 (58–71) 0.2919c
Male 55 65.5 41 60.3 14 87.5
0.045a
Female 29 34.5 27 39.7 2 12.5
Smoking
Former smoker 19 22.6 12 17.6 7 43.8
0.025a
Smoker 6 7.1 5 7.3 1 6.2
Non-smoker 46 54.8 42 61.8 4 25.0
Unknown 13 15.5 9 13.2 4 25.0
Underlying conditions
Diabetes mellitus 12 14.3 8 11.8 4 25.0 0.230b
COPD 5 5.6 2 2.9 3 18.8 0.045a
Coronary heart disease 12 14.3 7 10.3 5 31.3 0.046a
Hypertension 31 36.9 26 38.2 5 31.3 0.602b
Chronic hepatitis B 2 2.4 1 1.5 1 6.3 0.347a
Cerebrovascular disease 2 2.4 2 2.9 0 0.0 NA
Former or still oncologic diseases 7 8.3 6 8.8 1 6.3 0.738a
Chronic renal failure 3 3.6 3 4.4 0 0.0 NA
Medication at admission
Prior therapy with ACE inhibitor 15 17.9 12 17.6 3 18.9 1.000a
Prior therapy with sartan 11 13.1 9 13.2 2 12.5 1.000a
Median of days from the onset of symptoms to the nasal swab 6.5 (4–9) 7 (5–9) 5 (3–7.5) 0.0688c
History of contact with a confirmed or suspected case in the 
previous 14 days 16 19.1 13 24.5 3 9.7 0.149
a
Horowitz index at the baseline, median 324 (281–360) 332 (300–364) 280 (234–316) 0.0048c
Radiologically confirmed pneumonia 73 86.9 57 83.8 16 100.0 0.084b
Medication during hospitalisation
Empiric antibiotic therapy 44 52.4 30 44.1 14 87.5 0.002b
Protease inhibitors 72 85.7 57 83.8 15 93.8 0.307b
Hydroxychloroquine 71 84.5 55 80.8 16 100.0 0.057b
High Flow with Nasal Cannula > 24h 9 10.7 8 11.7 1 6.2 NA
Outcome at 3 April (data cut off)
Death 8 9.5 5 7.4 3 18.8
NADischarged 57 67.9 57 83.8 0 0.0
Still hospitalised 19 22.6 6 8.8 13 81.3
ACE: angiotensin converting enzyme; COVID-19: coronavirus disease; COPD: chronic obstructive pulmonary disease; ICU: intensive care unit; 





Clinical and demographic characteristics are summa-
rised in Table 1.
Additionally, two women, both in the second trimester 
of pregnancy, were hospitalised.
Corticosteroid treatment was only prescribed in N-ICU 
patients (n = 14; 20.6%) in the post-intervention 
period. Overall, three patients received tocilizumab: 
two in N-ICU and one in ICU. Four patients received 
remdesivir (5.9%), all in N-ICU.
Clinical and laboratory characteristics
Among laboratory parameters at the admission to the 
ward, we found a higher median of neutrophils and pro-
calcitonin in N-ICU patients. Moreover, a higher median 
of C-reactive protein was observed in ICU patients com-
pared with N-ICU (126 mg/L (IQR 72–209) and 44 mg/L 
(IQR 19–71) respectively; p < 0.0001). Although at the 
admission interleukin-6 was only available for 65 of 84 
patients, we observed a significant difference in the 
two groups* (Table 2).
We did not find any particular variation in clinical pres-
entation between patients transferred or not to ICU, 
except for diarrhoea which was more common in the 
N-ICU group (Table 3). Notably, three patients had an 
atypical presentation without fever: two syncopes, one 
abdominal pain. Data on self-reported dysgeusia and 
anosmia were available only for 48 N-ICU of 68 cases, 
and reported by 54.1% and 35.4%, respectively.
Clinical characteristics in the pre-
intervention and post-intervention period
We observed no difference in age, having COPD, cor-
onary heart disease, chronic hepatitis B, cerebrovas-
cular disease, oncologic illness, chronic renal failure, 
Horowitz index at admission between COVID-19 cases 
during the pre-intervention or post-intervention phase. 
The percentage of patients with diabetes mellitus and 
hypertension was higher at pre-intervention compared 
with post-intervention (25.8% vs 7.6% and 58.1% vs 
24.5% respectively) (Table 4).
In the pre- and post-intervention period, nine (29.0%) 
and seven (13.2%) patients were transferred to ICU. 
The overall rate of ICU transfers in our unit was 2.64 
(95% confidence interval (CI): 1.62–4.31) per 100 
patient days. The rate of ICU transfers in the post-
intervention period compared with the pre-intervention 
period markedly decreased from 6.30 per 100 patient 
days, (95% CI: 3.00–13.22) to 1.82 patient days, (95% 
CI: 0.94–3.50). The unadjusted rate ratio (RR) for trans-
fers for the post-intervention period was 0.28 (95% CI: 
0.10–0.75; p = 0.0070). After adjustment for sex, age, 
Horowitz index at baseline, diabetes mellitus, hyper-
tension, COPD, coronary heart disease, the RR for the 
post-intervention period was 0.88 (95% CI: 0.82–0.95; 
p = 0.002).
Discussion
The majority of cases hospitalised at ICT during the first 
30 days of the COVID-19 pandemic were males older 
than 60 years of age. More than half of them had at 
Table 2
Laboratory parameters at the admission of hospitalised COVID-19 cases at the infectious and tropical diseases unit of the 















Median IQR Median IQR Median IQR
White blood cells x 109/L, 
median 4.00–10.00 5.2 4.03–7.5 4.9 4.0–5.9 8.3 5.1–11.7 0.0028
Neutrophils x 109/L 1.50–7.50 3.7 2.8–5.5 3.4 2.6–4.9 6.0 4.2–10.2 0.0004
Lymphocytes 109/L 0.50–5.00 0.81 0.6–1.3 0.83 0.7–1.31 0.5 0.4–0.9 0.0209
Platlets 140–440 175 145–226 174 145–219 195 139–255 0.6442
Haemoglobin g/dl 14.0–18.0 13.7 11.4–14.8 13.7 12.6–14.9 13.6 11.3–14.6 0.2364
ALT (U/L) 10–50 24 16–44 24 15–43 23 18–54 0.7074
Creatinine (mg/dL) 0.70–1.20 0.9 0.8–1.1 0.9 0.7–1.0 1.0 0.8–1.1 0.2389
Sodium (mEq/L) 135–145 138 136–140 138 136–140 137 134–139 0.3903
Potassium (mEq/L) 3.5–5.1 4 3.7–4.3 4 3.7–4.3 3.9 3.6–4.3 0.5742
Procalcitonin (ng/mL) < 0.5 0.12 0.07–0.23 0.09 0.06–0.16 0.29 0.17–2.07 < 0.0001
LDH (U/L) 135–225 251 199–323 239 195–284 325 259–407 0.0014
IL-6 (pg/mL)a 0.0–10.0 14.7 6.8–28.4a 12.2 4.7–26.0a 48.5 17.0–90.7a <0.0001
C-reactive protein (mg/L) < 5 53 24–103 44 19–71 126 72–209 < 0.0001
ALT: alanine aminotransferase; COVID-19: coronavirus disease; ICU: intensive care unit; IL: interleukin; IQR: interquartile range; LDH: lactate 
dehydrogenase.
a Available for 65 patients: 51 not transferred in ICU, 14 transferred in ICU
b Kruskal-Wallis test.
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least one comorbidity of which hypertension, coronary 
heart disease, diabetes mellitus were most frequent, 
oncologic illness former or still, COPD, chronic renal 
failure, chronic hepatitis B and cerebrovascular disease 
were also present in a notable number of patients. We 
observed that the limited number of cases for which 
information was available, self-reported olfactory 
and/or taste disorders in 35% and 54%, which was 
higher compared with a recent Italian study [3]. It was 
not possible to precisely estimate if these symptoms 
preceded or followed those that prompted medical 
referral. However, anosmia and dysgeusia should be 
considered as possible clinical indication of COVID-19 
and lead to further investigation including testing for 
infection with severe acute respiratory syndrome coro-
navirus 2 (SARS CoV-2) [4].
Comparing admission characteristics between ICU and 
non-ICU cases, we found that COPD and Horowitz index 
at the time of hospitalisation were associated with ICU 
transfer in our series of COVID-19 cases (Table 1). The 
median days from the onset of symptoms to nasal 
swab was shorter for cases transferred to ICU probably 
because of a more severe clinical picture. Concerning 
laboratory results, we noticed a difference at admis-
sion in C-reactive protein and IL-6 levels between the 
two groups, leading us to speculate that those param-
eters could be early markers for ICU transfer* [5,6].
The overall proportion of cases transferred to ICU 
described here is higher compared with a Chinese 
cohort [7]. However, in our preliminary analysis, we 
observed a 12% reduction in ICU transfer rate adjusted 
for comorbidities between the pre- and post- interven-
tion period (p = 0.002). This benefit is represented by 
avoiding endotracheal intubation, taking out possible 
infectious risks. However, endotracheal intubation 
should not be delayed in patients with haemodynamic 
instability, multiorgan failure, or abnormal mental sta-
tus [8]. Unfortunately, we could not now evaluate if the 
intervention had an impact also on mortality, because 
19 (22.6%) patients were still hospitalised, and mor-
tality rate could have been underestimated in N-ICU. 
Current evidence against corticosteroid application in 
COVID-19 is unclear, but the Chinese Thoracic Society 
recently developed an expert consensus statement on 
the use of corticosteroids SARS-CoV-2 pneumonia [9]. 
The increase in corticosteroid prescriptions in the post-
intervention period could have played a role in reduc-
ing ICU transmission rate. Because of the small sample 
size and limited outcome information, we could not run 
a solid multivariable analysis and these results should 
be cautiously interpreted.
In conclusion, in this Italian cohort, the majority were 
men older than 60 years with at least one comorbid-
ity in nearly 60%. A self-reported anosmia and/or dys-
geusia were frequent symptoms similar to what has 
been described in a recent European and Italian study 
[3,4]. The rising intensity of care seemed to reduce 
the ICU transfer rate and endotracheal intubation. The 
main limitation of this study is the small sample size 
analysed.
Table 3
Symptoms of hospitalised COVID-19 cases at admission to the infectious and tropical diseases unit of University Hospital, 














n % n % n %
Fever >38° C 73 86.9 59 86.8 14 – 0.937c
Cough 59 70.2 50 73.5 9 56.2 0.174c
Dysgeusiaa 26 54.1a 26 54.1a NA – –
Dyspnoea 25 29.8 18 26.5 7 43.8 0.174c
Anosmiaa 17 35.4a 17 35.4a NA – –
Asthenia 19 22.6 16 23.5 3 18.7 1.000b
Diarrhoea 16 19.0 16 23.5 0 0.0 –
Myalgia/arthralgia 10 11.9 9 13.2 1 6.3 0.679b
Sputum 9 10.7 8 11.8 1 6.3 1.000b
Headache 7 8.3 7 10.3 0 0.0 –
Nausea/vomit 7 8.3 7 10.3 0 0.0 –
Sore throat 5 5.9 5 7.3 0 0.0 –
Nasal congestion 4 4.8 4 5.8 0 0.0 –
Rash 2 2.4 2 2.9 0 0.0 –
COVID-19: coronavirus disease; ICU: intensive care unit; NA: not available.





Upon the authors’ request, the following corrections 
were made on 11 May 2020, after publication of the 
article: the number of patients discharged at the cut-off 
date was corrected. Furthermore, in Table 1, numbers 
for ‘High Flow with Nasal Cannula > 24h’ were corrected 
and under ‘Clinical and laboratory characteristics’, the 
number of patients for whom information on IL-6 (pg/
mL) results was available was wrong in the text and in 
Table 2 and corrected. The corrections referring to IL-6 
(pg/mL) serum levels resulted in a statistically signifi-
cant difference, where there was no difference in the 
original publication, between ‘Not ICU transferred’ and 
‘ICU transferred’ patients. Consequently, one of the 
conclusions was changed from ‘Concerning laboratory 
results, we did NOT notice any difference at admission 
in IL-6 levels between the two groups, leading us to 
speculate that the included patients were in an early 
stage of the disease and IL-6 production might be trig-
gered in the later stages only [5,6].’ to ‘Concerning lab-
oratory results, we noticed a difference at admission 
in C-reactive protein and IL-6 levels between the two 
groups, leading us to speculate that those parameters 
could be early markers for ICU transfer [5,6].’ Together 
with these corrections, footnotes were added to Tables 
1,2 and 4 to indicate variables for which Kruskal-Wallis 
test was applied.
The authors apologise for the inconvenience.
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Francesco Liotta, Lorenzo Cosmi, Alessandra Vultaggio, 
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Table 4*
Clinical characteristics at admission of COVID-19 cases hospitalised before and after the implementation of additional 
intensive care measures at the infectious and tropical diseases unit of University Hospital, Florence, Italy, 25 February–26 







n = 53 p value
n % or (IQR) n % or (IQR)
Age and sex
Age, median (years) 64 (58–72) 59 (50–51) 0.1822c
Male 19 61.3 36 67.9
0.537b







































Diabetes mellitus 8 25.8 4 7.6 0.028a
COPD 2 6.5 3 5.7 1.000a
Coronary heart disease 5 16.1 7 13.2 0.712b
Hypertension 18 58.1 13 24.5 0.002b
Chronic hepatitis B 1 3.2 1 1.9 1.000a
Cerebrovascular disease 1 3.2 1 3.2 1.000a
Former or still oncologic diseases 3 9.7 4 7.6 0.705a
Chronic renal failure 1 3.2 2 3.8 1.000a
Horowitz index at the baseline, median 306 (276–347) 328 (295–366) 0.1029c
C-reactive Protein (mg/L), median 
 
(Norm:  < 5 mg/L)
50 (25–82) 64 (17–133) 0.4169c
COPD: chronic obstructive pulmonary disease; COVID-19: coronavirus disease; IQR: interquartile range.
a Fisher’s exact test.
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